|
1
|
Scott AJ, Messersmith WA and Jimeno A:
Apatinib: A promising oral antiangiogenic agent in the treatment of
multiple solid tumors. Drugs Today (Barc). 51:223–229.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wu F, Zhang S, Xiong A, Gao G, Li W, Cai
W, Su C, Chen X, Zhou F, Zhao J, et al: A phase II clinical trial
of apatinib in pretreated advanced non-squamous non-small-cell lung
cancer. Clin Lung Cancer. 19:e831–e842. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma
JP, Yang J, Xie P and Zhang Z: Comparison of efficacy between TACE
combined with apatinib and TACE alone in the treatment of
intermediate and advanced hepatocellular carcinoma: A single-center
randomized controlled trial. Cancer Biol Ther. 18:433–438.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple negative breast cancer. Int J
Cancer. 135:1961–1969. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L,
Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of
apatinib in non-triple-negative metastatic breast cancer. BMC
Cancer. 14(820)2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang Y, Han C, Li J, Zhang L, Wang L, Ye
S, Hu Y and Bai L: Efficacy and safety for Apatinib treatment in
advanced gastric cancer: A real world study. Sci Rep.
7(13208)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Evered D and Hall R: Hypothyroidism. Br
Med J. 1:290–293. 1972.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
11
|
Park VY, Kim EK, Kwak JY, Yoon JH, Kim MJ
and Moon HJ: Thyroid imaging reporting and data system and
ultrasound elastography: Diagnostic accuracy as a tool in
recommending repeat fine-needle aspiration for solid thyroid
nodules with non-diagnostic fine-needle aspiration cytology.
Ultrasound Med Biol. 42:399–406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chatterjee S, Heukamp LC, Siobal M,
Schottle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K,
Meder L, et al: Tumor VEGF: VEGFR2 autocrine feed-forward loop
triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Zhang Q, Yu C, Peng S, Xu H, Wright E,
Zhang X, Huo X, Cheng E, Pham TH, Asanuma K, et al: Autocrine VEGF
signaling promotes proliferation of neoplastic Barrett's epithelial
cells through a PLC-dependent pathway. Gastroenterology.
146:461–472 e6. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Oudard S, Beuselinck B, Decoene J and
Albers P: Sunitinib for the treatment of metastatic renal cell
carcinoma. Cancer Treat Rev. 37:178–184. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Abdel-Rahman O: Systemic therapy for
hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl
Canc Inst. 25:165–171. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lin ZZ, Chen BB, Hung YP, Huang PH, Shen
YC, Shao YY, Hsu CH, Cheng AL, Lee RC, Chao Y and Hsu C: A
multicenter phase II study of second-line axitinib for patients
with advanced hepatocellular carcinoma failing first-line sorafenib
monotherapy. Oncologist 2020 (Epub ahead of print).
|
|
17
|
Clark JW, Eder JP, Ryan D, Lathia C and
Lenz HJ: Safety and pharmacokinetics of the dual action Raf kinase
and vascular endothelial growth factor receptor inhibitor, BAY
43-9006, in patients with advanced, refractory solid tumors. Clin
Cancer Res. 11:5472–5480. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mendel DB, Laird AD, Xin X, Louie SG,
Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et
al: In vivo antitumor activity of SU11248, a novel tyrosine kinase
inhibitor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: Determination of a
pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res.
9:327–337. 2003.PubMed/NCBI
|
|
19
|
Rovesti G, Orsi G, Faloppi L, Gramantieri
L, Silvestris N, Marisi G, Foschi F, Tamburini E, Andrikou K,
Molinaro E, et al: Sorafenib in patients with hepatocellular
carcinoma: 10 years of real life. Ann Oncol. 30 (Suppl
4)(S57)2019.
|
|
20
|
Flaherty KT, Manola JB, Pins M, McDermott
DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA and DiPaola RS:
BEST: A randomized phase II study of vascular endothelial growth
factor, RAF kinase, and mammalian target of rapamycin combination
targeted therapy with bevacizumab, sorafenib, and temsirolimus in
advanced renal cell carcinoma-a trial of the ECOG-ACRIN cancer
research group (E2804). J Clin Oncol. 33:2384–2391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Worden F, Fassnacht M, Shi Y, Hadjieva T,
Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, et al:
Safety and tolerability of sorafenib in patients with
radioiodine-refractory thyroid cancer. Endocr Relat Cancer.
22:877–887. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Thorn CF, Sharma MR, Altman RB and Klein
TE: PharmGKB summary: Pazopanib pathway, pharmacokinetics.
Pharmacogenet Genomics. 27:307–312. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Doherty KR, Wappel RL, Talbert DR, Trusk
PB, Moran DM, Kramer JW, Brown AM, Shell SA and Bacus S:
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib,
erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl
Pharmacol. 272:245–255. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tian S, Quan H, Xie C, Guo H, Lue F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mannavola D, Coco P, Vannucchi G,
Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P and Fugazzola L:
A novel tyrosine-kinase selective inhibitor, sunitinib, induces
transient hypothyroidism by blocking iodine uptake. J Clin
Endocrinol Metab. 92:3531–3534. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rini BI, Tamaskar I, Shaheen P, Salas R,
Garcia J, Wood L, Reddy S, Dreicer R and Bukowski RM:
Hypothyroidism in patients with metastatic renal cell carcinoma
treated with sunitinib. J Natl Cancer Inst. 99:81–83.
2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wong E, Rosen LS, Mulay M, VanVugt A,
Dinolfo M, Tomoda C, Sugawara M and Hershman JM: Sunitinib induces
hypothyroidism in advanced cancer patients and may inhibit thyroid
peroxidase activity. Thyroid. 17:351–355. 2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tamaskar I, Bukowski R, Elson P,
Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J and Rini BI:
Thyroid function test abnormalities in patients with metastatic
renal cell carcinoma treated with sorafenib. Ann Oncol. 19:265–268.
2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wolter P, Stefan C, Decallonne B, Dumez H,
Bex M, Carmeliet P and Schöffski P: The clinical implications of
sunitinib-induced hypothyroidism: A prospective evaluation. Br J
Cancer. 99:448–454. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Clemons J, Gao D, Naam M, Breaker K,
Garfield D and Flaig TW: Thyroid dysfunction in patients treated
with sunitinib or sorafenib. Clin Genitourin Cancer. 10:225–231.
2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Feldt S, Schussel K, Quinzler R, Franzmann
A, Czeche S, Ludwig WD and Schulz M: Incidence of thyroid hormone
therapy in patients treated with sunitinib or sorafenib: A cohort
study. Eur J Cancer. 48:974–981. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Baffert F, Le T, Sennino B, Thurston G,
Kuo CJ, Hu-Lowe D and McDonald DM: Cellular changes in normal blood
capillaries undergoing regression after inhibition of VEGF
signaling. Am J Physiol Heart Circ Physiol. 290:H547–H559.
2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Alexandrescu DT, Popoveniuc G, Farzanmehr
H, Dasanu CA, Dawson N and Wartofsky L: Sunitinib-associated
lymphocytic thyroiditis without circulating antithyroid antibodies.
Thyroid. 18:809–812. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Walko CM, Aubert RE, La-Beck NM, Clore G,
Herrera V, Kourlas H, Epstein RS and McLeod HL:
Pharmacoepidemiology of clinically relevant hypothyroidism and
hypertension from sunitinib and sorafenib. Oncologist. 22:208–212.
2017.PubMed/NCBI View Article : Google Scholar
|
